Figure 6.

Effect of BITC administration on levels of osteoclast regulating factors in tumors of MMTV-neu mice. (A) Western blotting for RUNX2, sRANKL, nuclear factor-κB (NF-κB) p65, OPG and GAPDH using MMTV-neu tumor supernatants. Arrow indicates right band for OPG protein. (B) Quantitation of RUNX2, sRANKL, NF-κB p65 and OPG protein expression in tumors of control- and BITC-treated MMTV-neu mice. Columns indicate average and bars indicate standard deviation. P value was determined by unpaired Student’s t-test. (C) RNA-seq expression of RUNX2 and RANKL (TCGA dataset) in normal breast tissue (n = 114) and breast cancers of different subtypes, including normal-like (n = 23), Luminal A (LumA; n = 421), LumB (n = 192), human epidermal growth factor receptor 2 (n = 67) and basal-like (n = 141). P value was determined by one-way ANOVA with Bonferroni’s test.